376 related articles for article (PubMed ID: 32151660)
1. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
Polyzos SA; Kang ES; Boutari C; Rhee EJ; Mantzoros CS
Metabolism; 2020 Oct; 111S():154203. PubMed ID: 32151660
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.
Guirguis E; Grace Y; Bolson A; DellaVecchia MJ; Ruble M
Pharmacotherapy; 2021 Mar; 41(3):315-328. PubMed ID: 33278029
[TBL] [Abstract][Full Text] [Related]
3. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
4. Current and future pharmacological therapies for NAFLD/NASH.
Sumida Y; Yoneda M
J Gastroenterol; 2018 Mar; 53(3):362-376. PubMed ID: 29247356
[TBL] [Abstract][Full Text] [Related]
5. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
6. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
[TBL] [Abstract][Full Text] [Related]
7. [Treatment Options in Non-alcoholic Fatty Liver Disease].
Kim W
Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of drugs for nonalcoholic steatohepatitis.
Shen B; Lu LG
J Dig Dis; 2021 Feb; 22(2):72-82. PubMed ID: 33385317
[TBL] [Abstract][Full Text] [Related]
10. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
[TBL] [Abstract][Full Text] [Related]
11. Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Sumida Y; Yoneda M; Ogawa Y; Yoneda M; Okanoue T; Nakajima A
Expert Opin Pharmacother; 2020 Jun; 21(8):953-967. PubMed ID: 32237916
[TBL] [Abstract][Full Text] [Related]
12. [The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD].
Honda A; Ishii I
Yakugaku Zasshi; 2022; 142(12):1335-1343. PubMed ID: 36450511
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease: new treatments.
Hardy T; Anstee QM; Day CP
Curr Opin Gastroenterol; 2015 May; 31(3):175-83. PubMed ID: 25774446
[TBL] [Abstract][Full Text] [Related]
15. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
[TBL] [Abstract][Full Text] [Related]
16. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T
Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
[TBL] [Abstract][Full Text] [Related]
17. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease.
Kamata S; Honda A; Ishii I
Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627329
[TBL] [Abstract][Full Text] [Related]
18. RLA8-A New and Highly Effective Quadruple PPAR-
Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
[TBL] [Abstract][Full Text] [Related]
19. Emerging and future therapies for nonalcoholic steatohepatitis in adults.
Mintziori G; Polyzos SA
Expert Opin Pharmacother; 2016 Oct; 17(14):1937-46. PubMed ID: 27564402
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
Eshraghian A
World J Gastroenterol; 2017 Nov; 23(42):7495-7504. PubMed ID: 29204050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
